Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sleepwalking and Sleep Talking01:17

Sleepwalking and Sleep Talking

1.0K
Somnambulism, commonly known as sleepwalking, involves individuals engaging in activities ranging from simple walking to more complex behaviors such as driving. Sleepwalking typically occurs during the slow-wave sleep stages 3 and 4 early in the night when the person is not dreaming, contradicting the myth that sleepwalkers are acting out their dreams.
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
1.0K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

279
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
279
Patient-centered Care01:13

Patient-centered Care

3.1K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.1K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

278
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

241
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
241

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.

NPJ breast cancer·2023
Same author

Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience.

The oncologist·2023
Same author

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.

The oncologist·2023
Same author

Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.

Cancer treatment reviews·2023
Same author

Immunotherapy for inflammatory breast cancer: current evidences and future perspectives.

Current opinion in oncology·2023
Same author

Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer.

Current opinion in oncology·2023

Related Experiment Video

Updated: Feb 9, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Talking to patients about biosimilars.

Yelena Y Janjigian1, Marco Bissig2, Giuseppe Curigliano3

  • 1Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY 10065, USA.

Future Oncology (London, England)
|June 2, 2018
PubMed
Summary
This summary is machine-generated.

Biosimilars offer a lower-cost alternative to biologic therapies for diseases like cancer and diabetes. Increased awareness of these highly similar drugs can improve patient access and understanding of treatment options.

Keywords:
biosimilarhealthcare providerpatient accesspatient communicationregulatory pathwaytotality of evidence

More Related Videos

Expired CO2 Measurement in Intubated or Spontaneously Breathing Patients from the Emergency Department
07:52

Expired CO2 Measurement in Intubated or Spontaneously Breathing Patients from the Emergency Department

Published on: January 29, 2011

17.0K
Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies
06:35

Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies

Published on: April 5, 2024

1.5K

Related Experiment Videos

Last Updated: Feb 9, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Expired CO2 Measurement in Intubated or Spontaneously Breathing Patients from the Emergency Department
07:52

Expired CO2 Measurement in Intubated or Spontaneously Breathing Patients from the Emergency Department

Published on: January 29, 2011

17.0K
Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies
06:35

Author Spotlight: Insights into Cardiometabolic Diseases with Subcutaneous Adipose Tissue Microvasculature Studies

Published on: April 5, 2024

1.5K

Area of Science:

  • Biopharmaceutical science
  • Immunology
  • Pharmacology

Background:

  • Biologic therapies are crucial for treating complex diseases like diabetes, cancer, and autoimmune disorders.
  • Despite advancements, patient access to these life-changing treatments remains a significant challenge.
  • Biosimilars represent a promising solution to broaden access to effective biologic treatments.

Purpose of the Study:

  • To provide an overview of the scientific basis of biosimilars.
  • To discuss current indications and the role of biosimilars in patient treatment plans.
  • To enhance healthcare provider and patient understanding and discussions regarding biosimilars.

Main Methods:

  • Review of scientific literature on biosimilar development and regulatory approvals.
  • Analysis of comparative efficacy and safety data for approved biosimilars.
  • Examination of economic factors influencing biosimilar adoption and patient access.

Main Results:

  • Biosimilars are highly similar to originator biologics, demonstrating comparable efficacy and safety profiles.
  • Approved biosimilars are available in the USA and Europe, with potential for lower treatment costs.
  • A notable gap exists in awareness among healthcare providers and patients regarding biosimilars.

Conclusions:

  • Biosimilars offer a cost-effective pathway to expand patient access to advanced biologic therapies.
  • Increased understanding and awareness are essential for the successful integration of biosimilars into clinical practice.
  • Further education can empower patients and providers to confidently consider biosimilars in treatment strategies.